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Background: As a result of extensive chloroquine resistance (CQR) in Plasmodium falciparum in late 1990s, Ethiopia
replaced CQ with sulphadoxine-pyrimethamine (SP) as first-line drug, which in turn was replaced by artemisinin
combination therapy in 2004. Plasmodium falciparum resistance to CQ is determined by the mutation at K76T
of the P. falciparum chloroquine resistance transporter (pfcrt) gene. Understanding diversity in the P. falciparum
genome is crucial since it has the potential to influence important phenotypes of the parasite such as drug resistance.
Limited data is available regarding the type of pfcrt mutant allelic type, the effect of CQ withdrawal and diversity of the
parasite population in south-central Oromia, Ethiopia.
Methods: Finger-pricked blood spotted on Whatman 3MM filter papers were collected from falciparum malaria
patients. Parasite DNA was extracted from individual blood spots on the filter papers. The presence of K76T mutations
was determined using nested PCR for all isolates. Complete sequencing of mutations in pfcrt 72-76 was done for a set
of randomly selected resistant isolates. Four microsatellite (MS) markers were analysed to determine the heterozygosity.
Results: Although CQ was withdrawn for more than a decade, 100% of the parasites still carried the pfcrt K76T
mutation. All isolates were mutant at the K76T polymorphism. Based on combinations of MS markers, seven different
Ethiopian CQR variants (E1-E7) were identified. Heterozygosity (He) for MS flanking the pfcrt chloroquine resistance allele
ranged from 0.00 (mscrt -29, -29.268 kb) to 0.21 (mscrt -2, -2.814 kb). He ranged from 0.00 (msint 3, 0 kb) to 0.19 (msint
2, 0 kb) for MS within the pfcrt gene. Both intronic and MS flanking the pfcrt gene showed low levels of diversity.
Conclusion: pfcrt CQR allele seems to be fixed in the study area. Of the different haplotypes associated with CQR, only
the CVIET genotype was identified. No reversal to the wild-type has occurred in Ethiopia unlike in many Africa countries
where CQR parasites declined after cessation of CQ use. Decreased diversity in CQR isolates surrounding pfcrt suggests
CQ selection and homogenization among CQR parasite population. While mutation in msint 3 and mscrt -29 of the
mutant pfcrt allele is being fixed, it seems that mutations in msint 2 and mscrt -2 are still evolving and may indicate the
start of re-diversification of the population from a fixed 76 T population.
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The emergence and spread of CQR Plasmodium falcip-
arum in malaria-endemic countries has led to alterations
in the anti-malarial treatment policy and the introduc-
tion of artemisinin-based combination therapies (ACT)
for treatment of uncomplicated malaria [1]. The failure
of CQ to clear P. falciparum asexual parasites in Ethiopia
was first reported in 1986 in areas bordering Somalia,
Kenya and Sudan. A steady increase in the number of
refractory isolates was observed in all malarious areas
in Ethiopia and as a result CQR P. falciparum became
a major public health threat in 1990s [2]. In response
to high levels of P. falciparum resistance to CQ and
then sulphadoxine-pyrimethamine (SP), Ethiopia adopted
artemether-lumefantrine (AL or Coartem©) as first-line
therapy in 2004 [3-5]. According to the current national
malaria diagnosis and treatment guidelines, AL and CQ
are first-line treatment for uncomplicated P. falciparum
and Plasmodium vivax infections, respectively. For all
clinical infections without laboratory confirmation, AL,
which is effective against both P. falciparum and P. vivax,
is the first-line treatment. The reduced susceptibility of
parasite strains to artemisinin necessitates assessment
of the current status of CQR in Ethiopia. CQ is a drug
of interest for study because of its efficacy, affordability,
easy administration, prophylaxis potential, low toxicity
and relatively few side effects [4].
It has been recognized that CQR falciparum malaria is
caused by mutations in two genes, the P. falciparum CQ
resistance transporter (pfcrt) and multidrug resistance
transporter-1 (pfmdr1) however the former is a stronger
predictor of CQR than pfmdr1. Polymorphisms in the pfcrt
gene segregate precisely with two distinct drug response
classes, considered either CQS or CQR. All P. falciparum
clinical samples that are resistant to CQ contain the K76T
mutation [6]. Amino acid change from lysine to threonine
at position 76 (K76T) appears necessary for the resistance
phenotype and is the most reliable molecular marker of
resistance of the various pfcrt mutations. It is unfortunate
to notice that strains of P. falciparum resistant to arte-
misinin have appeared in the Cambodia–Thailand border
region [7]. While CQS strains are characterized by the
CVMNK haplotype, irrespective of geographic origin, two
major haplotypes defined by specific mutations at amino
acid positions 72-76 of pfcrt, CVIET and SVMNT, are
associated with the geographic origin of CQR [8]. The
former haplotype is predominantly found in Southeast
Asia and Africa, whereas the SVMNT haplotype is
characteristic of South America, Papua New Guinea [9],
and the Philippines [10].
A decrease in drug resistant pfcrt alleles has been
reported following discontinuation of drug pressure
[11] in Africa although this process can vary greatly
between countries. A long-term decline in the use ofCQ can lead to resurgence of drug-sensitive populations
of P. falciparum. This raises the possibility that, in time,
the drug could be re-introduced [12]. Understanding the
influence of CQ withdrawal on local malaria parasite
populations has great significance. In Malawi, for instance,
the frequency of the mutation declined from 85% in 1992
to 13% in 2000 in one study [13] and from 17% in 1998 to
2% in 2000 in another study [14] after CQ was withdrawn
as the first- line drug. Studies in Kenya [15] and China
[16] have reported complete and partial recovery of
CQS parasites after the use of CQ was abandoned. This
recovery was thought to be due to the re-introduction
of susceptible parasites harbouring a CQS pfcrt [17,18],
although the possibilities of back mutation in pfcrt at
position 76 may not be underestimated. Continued sur-
veillance of markers of resistance to withdrawn drugs
has been indicated with the prospect that decreases in
resistance may make it possible to reuse this safe and
cheap drug [4,17]. The overall trend in the reversal of the
resistance could be related to a country’s drug policies
although data regarding the impact of CQ withdrawal
on circulating parasite population is not well studied in
Ethiopia.
When advantageous mutations such as drug resistance
mutations spread through a population, unrelated markers
that flank these loci are carried along through linkage
disequilibrium by a “hitch-hiking effect”, thereby removing
genetic variation from chromosomal regions surrounding
the locus [19]. Unlike in CQS alleles, there is a marked
drop in variability and an increase in linkage disequilib-
rium with CQR associated alleles in ~40 kb region flanking
the pfcrt gene [8]. MS repeats, occurring on the average
approximately every 1 kb [20,21], are common in the
P. falciparum genome and have been recently used to
analyse both intra- and inter-population relationships
among drug-resistant P. falciparum strains.
Drug treatment has not only resulted in positive selection
at codons conferring resistance but also alleles at loci
closely linked to these genes, due to limited recombination
in the chromosome regions containing these genes since
drug selection was imposed [22]. If a particular mutation
in the target molecule is fixed in the parasite population
due to the drug pressure, its flanking MS markers will
start showing minimum variation [23]. Thus, selective
sweeps for drug-resistant genotypes may have restricted
the genetic diversity of this parasite [8]. MS markers
associated with drug resistance enabled identification
of drug resistance origin as well as tracing spread of
these mutations [24]. Drug- resistant genotypes are
characterized by reduced diversity around the major
resistant alleles [25]. Thus, the expected heterozygosity
(He) values of the flanking MSs will be reduced among
mutant parasites. Diversity of haplotypes existed in the
parasite population before CQR but after the selection,
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those with pfcrt76T survive and expand in the population.
Thus, in areas where CQ has been widely used, there will
be homogeneity of the loci in this chromosome region of
the resistant parasites around the pfcrt whereas diversity
of MS alleles will still be found in sensitive parasites.
Despite high level of CQR in Ethiopia, pertinent data
regarding the type of mutant pfcrt genotype are lacking.
Applications of MS markers flanking the genes have
revealed that drug resistance appears to have resulted
from the migration of limited resistant lineages to many
endemic regions however the resistance haplotypes present
in Ethiopia is not known. Despite the migration of resistant
lineages, multiple resistant lineages independently evolved
in several endemic regions. Indeed, the geographic origin
and spread of resistance can be estimated by the genotyp-
ing of pfcrt at positions 72-76 and MS haplotyping flanking
this locus. Although Ethiopia is highly endemic for P.
falciparum malaria and CQR P. falciparum isolates occur
widely, there is scarcity of data regarding the pfcrt
genotypes and diversity among the parasite population.
Authors hypothesize that although CQ was replaced by
ACT for treatment of P. falciparum malaria in the coun-
try, unlike in many African countries, the withdrawal CQ
may not result in the reduction of CQR genotype for the
fact that it is still the first-line treatment for P. vivax and
co-infections are inevitable. The purpose of this study was,
therefore, to determine the CQR haplotypes, to unveil the
magnitude of P. falciparum CQR genotypes 14 years after
its withdrawal and to determine the genetic diversity in
CQR alleles in south-central Oromia, Ethiopia.
Methods
Study area and population
The study was conducted in Shalla District (07 17′ 34.2 S,
038′ 21″’ 46.3 W), West Arsi Zone, Oromia, located
251 km from, Addis Ababa, Ethiopia. The district is
1500-2300 m above sea level. It has a land-mass of
about of 5,932 sq km with a projected population of
176,671 living in malarious areas. The area is character-
ized by relatively high rates of poverty. The inhabitants
are mainly supported by rain-dependent cultivation of
maize, tef (Eragrostis tef ), wheat and sorghum. In the
study area, malaria is caused by two dominant species,
P. falciparum and P.vivax. The area experiences distinct
wet and dry seasons. Malaria transmission is seasonal and
unstable in the study area.
Collection of Plasmodium falciparum isolates
A total of 99 P. falciparum isolates were collected in
Shalla District from November through December 2012.
Detailed procedures for parasite collection were previ-
ously described [26]. Forty-nine isolates were collected
from febrile (clinical/symptomatic) patients and 50 fromasymptomatic subjects during community-based screening
of asymptomatic P. falciparum carriers. Malaria diagnosis
was done by rapid diagnostic test (RDT) (SD BIOLINE
Malaria Ag P.f/P.v POCT test kits, Standard Diagnostic,
Inc, Germany, LOT No:145021) under field conditions
and microscopy at Adama/Nazareth Malaria Control
Centre. Finger-prick blood samples were spotted on
Whatman 3MM filter papers for parasite DNA extraction.
DNA extraction and RFLP-PCR
Parasites DNA were extracted from blood spotted on
Whatman 3MM filter papers using the chelex extraction
method [27]. DNA was prepared from 3-mm discs re-
moved from each blood spot using a sterile hole-punch.
The cut section of the spot was soaked in a 1 ml, 0.5%
saponion-1x phosphate buffered saline (PBS) overnight
in a 96-deep-well plate. The cut section of filter paper
was then washed twice in 1xPBS, and was then boiled
for 10 min in 100 μl PCR quality water with 50 μl 20%
chelex suspension (pH 9.5). DNA was amplified by nested
PCR (LifePro thermal cycler Bioer). The restriction frag-
ment length polymorphism (RFLP) protocol was used
to identify the K76T mutation, essentially as described
previously [6]. For restriction enzyme digestions, PCR
products were used without purification. Five μl of the
nested-PCR products were digested with one unit of
ApoI restriction enzyme at 55°C for three hours, which
yielded two fragments (100 bp and 45 bp) on 2% agarose
gel in the case of wild-type (K76), but it remained uncut
(hence one band) when the 76 T mutation was present.
Both PCR products and digestion fragments were visual-
ized by ethidium bromide under UV light.
pfcrt genotyping and sequencing
Determination of polymorphisms at pfcrt was performed
by PCR-RFLP method. The pfcrt gene was amplified
by nested PCR using two sets of primers designed to
amplify a region of exon 2 including known polymorphic
sites at amino acid positions 72-76. Primer sequences and
PCR conditions were as shown elsewhere [28]. Apo I,
which cuts the K76 codon, was used to distinguish wild-
type from the mutant. After screening the PCR products
on agarose gel to identify the resistant and the wild type,
the primary products of nested PCR-RFLP resistant to
the ApoI (Fermentas) digestion, showing only one band
(mutant genotypes), were subjected to DNA sequencing.
Samples were purified before sequencing using GeneJET
PCR purification kit (Thermo Scientific, Lithuania) and
sequenced using an automatic sequencer ABI3730 at
Uppsala Genome Centre (Uppsala University, Sweden).
Microsatellite analysis
Four highly polymorphic MS loci (msint 2, msint 3,
mscrt -2 and mscrt -29) were used for determining
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markers (msint 2 and msint 3) were located in introns
and the other two (mscrt -2 and mscrt -29) were flanking
loci situated downstream of the pfcrt gene [8,20,21]. MS
variations in the number of repeats in pfcrt were measured
using a PCR protocol previously described [29]. Briefly,
each MS marker was amplified by semi-nested PCR in a
LifePro thermal cycler (Bioer) in 20 μl reaction containing
2 μl of genomic DNA template, 0.5 unit of Taq polymer-
ase, 2.5 μl of 10× reaction buffer, and 0.4 mM of each
dNTP. Cycling parameters were set for each primer pairs.
Length variation of labelled PCR products was measured
on an ABI PRISM 3730XL DNA Analyzer (Applied Bio-
systems, Sweden). The GENESCAN and GENOTYPER
software (Applied Biosystems) were used to measure allele
length and to quantify peak heights. Haplotypes were clas-
sified as different if they contained ≥ one different alleles
across all loci. Samples presenting multiple alleles at any
of the four loci were considered mixed infections and were
not used for multilocus MS haplotype construction and
other analyses. Nevertheless, it is possible that nonspecific
marker binding will cause noise in the form of minor peak
heights during the capillary electrophoresis reaction. As a
result, the standard method is to exclude minor peaks less
than one third the height of the major peaks (alleles) [30].
MS haplotypes were determined for all pfcrt mutant
isolates. During every MS reaction, a Dd2 reference isolate
was included as a positive control while water was used as
negative control.Ethical clearance
Study protocols were reviewed and approved by Institu-
tional Review Boards of Aklilu Lemma Institute of Pathobi-
ology, Addis Ababa University and of the Armauer Hansen
Research Institute as well as the National Research Ethics
Review Committee. Ahead of enrolment, written informed
consent was obtained from all study subjects. In the case
of children, consent was obtained from a parent or legal
guardian. Illiterate people signed with their fingerprint.Statistical analysis
The genetic variation in terms of expected heterozygosity
(He) for each MS locus was calculated using the following
formula, He = [n/ (n-1)] [1-ΣPi
2] where n is the number of
alleles in the sample and p is the frequency of the ith allele.
When two or more polymorphisms were detected, the
isolates were considered to be mixed infections and
thus excluded from the analysis. He values ranges from
0 to 1 where 0 means that there is no difference between
individual isolates and 1 means that all individual isolates
are unique and population groups are distinct from
each other.Results
Prevalence of molecular markers for pfcrt
Results from this study provide important information
about the effect of CQ usage on the population structure
of Ethiopian P. falciparum parasites. In this study, pfcrt
K76T mutation involved in CQR analysed in 99 P. falcip-
arum samples (forty-nine from clinical patients and 50
from asymptomatic subjects) collected 14 years after
withdrawal of CQ for the treatment of uncomplicated
P. falciparum from the study areas. Analysis of samples
showed that 100% (n = 99) of the patients harboured the
pure mutant allele of pfcrt 76 T. Twenty of the fragments
that were resistant to ApoI digestion (76 T genotype)
were randomly selected for complete sequence for amino
acids positions 72-76. All the isolates harboured the
pfcrt-CVIET genotype. No single wild-type, CVMNK
pfcrt genotype, was detected in the study area.
Mapping of genetic relatedness of resistance mutants
To analyse the genetic relatedness of the alleles carrying
the CVIET haplotype, intronic (msint 2, msint 3) and
flanking (mscrt -2, mscrt -29) MS loci were analysed
for all the isolates included in this study. Of 99 isolates
harbouring pfcrt mutant genotypes, 79 samples were
successfully analysed for MS haplotypes. Using four MS,
there were 79 single-clone infections. In eight of the
isolates MS were not successfully amplified and excluded
from analysis. Twelve samples were also not included
in calculating allelic frequencies because they had either
multiple alleles (>one peak in the sequencing electrophe-
rogram) or missing data at one or more codons. 85.7%
(10/12) of the samples presenting multiple alleles and
hence excluded from analysis were those collected from
asymptomatic individuals. Thus, MS analysis was done
for 79 mutant isolates. There were seven unique MS
haplotypes detected in the 79 P. falciparum isolates. To
assess the genetic relatedness of pfcrt mutants, a size-based
haplotype variations at all MS markers was constructed.
Haplotype was defined as the specific combination of the
alleles of the following four MS markers: msint 2 (0 kb),
msint 3 (0 kb), mscrt -2 (-2.814 kb) and mscrt -29
(-29.268 kb). Only one intronic and one flanking marker
showed more than one allele (Table 1). The number of al-
leles per locus ranged from one (at msint 3 and mscrt -29)
to four (msint 2). Heterozygosity values were 0.19 and 0.21
for msint 2 and mscrt -2, respectively (Table 2). Reduced
variation in markers spanning a -29 kb region around pfcrt
was observed in the study area.
Microsatellite analysis of isolates from symptomatic and
asymptomatic subjects
The 79 isolates with CVIET belonged to seven closely
related haplotypes. Alleles were determined as differences
in repeat length. There were seven different Ethiopian
Table 1 pfcrt allelic types defined by mutations in positions amino acids 72-76 and polymorphisms in MS markers
(intronic and flanking) in 79 P. falciparum isolates in Shalla district, south-central Oromia, Ethiopia
Haplotype ID
MS distance from pfcrt pfcrt genotype/a.a
at pfcrt 76












E1 149 179 198 204 CVIET 35 30 65 82.3%
E2 149 181 198 204 CVIET 3 2 5 6.3%
E3 149 179 198 209 CVIET 0 2 2 2.5%
E4 149 179 198 215 CVIET 1 1 2 2.5%
E5 149 179 198 197 CVIET 0 1 1 1.3%
E6 149 181 198 215 CVIET 3 0 3 3.8%
E7 149 177 198 204 CVIET 1 0 1 1.3%
Haplotypes ID (E1-E7) were classified as different if they contained ≥ one different alleles across all loci. Allelic size at each MS locus is shown.
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prevalent haplotype, E1, (n = 65) had allelic combination
of 204-198-179-149 at the MS loci of 0 kb, 0 kb, -2.814 kb
and -29.268 kb, respectively (Table 1). The other hap-
lotypes, E2 (n = 5), E3 (n = 2), E4 (n = 1), E5 (n = 1), E6
(n = 3) and E7 (n = 2) and their respective allelic combina-
tions is found in Table 1. Three allelic combinations in E1,
E2 and E4 were shared among all the mutant isolates at
the MS loci of msint 2, msint 3, mscrt -2 and mscrt -29,
respectively. Two allelic combinations in E6 and E7 were
specific to isolates collected from clinical patients. Two
other allelic combinations in E3 and E5 were found only
in isolates collected from asymptomatic subjects. Strong
CQ selection together with low local recombination rates
(low intensity of transmission) in the study area may
account for reduced variation at pfcrt. Allelic sizes of
the four MS with respect to all the isolates are found in
Additional file 1.
Discussion
The widespread resistance to CQ and other-antimalarials
occurring in Ethiopia has fostered the deployment of ACT
for falciparum malaria. ACT (AL/Coartem©), has been
the choice of P. falciparum therapy in Ethiopia since
2004. At the time of CQ withdrawal, the prevalence of the
pfcrt-76 T resistance marker was estimated to have been
100% [31] in Ethiopia. Meanwhile, declining resistance toTable 2 Number of alleles and expected heterozygosity
per MS locus for pfcrt on chromosome 7 (n = 79)




He Mean (±s. d)
Msint 2 0 kb 4 0.19 (0.05)
Msint 3 0 kb 1 0.00 (0.00)
Mscrt -2 -2.814 kb 3 0.21 (0.05)
Mscrt -29 -29.268 kb 1 0.00 (0.00)
aUpstream distances were calculated from the gene’s start codon and
downstream distances were calculated from the gene’s stop codon.CQ observed in P. falciparum in many malarious regions
after its withdrawal suggests a possibility of future reintro-
duction of the drug.
In this study the prevalence of K76T mutation was
100% although CQ has been withdrawn since 1999 in
Ethiopia. The fact that all isolates were mutant mean that
reversal from CQR to wild-type has not occurred and the
parasites seem under continuous selection pressure of
CQ. The high level of pfcrt K76T mutation observed in
this study is in agreement with a study done in a rural
hospital in southern Ethiopia [32]. For various reasons,
drug resistance is expected to drop after the removal of
selective pressure [33] although CQR has remained high
in the study site (Ethiopia) which is in concordance with a
study conducted in Yunnan Province, China [33]. It is
highly likely that the use of CQ as a first-line treatment for
P. vivax, which accounts for approximately 40% of all
malaria cases, may have contributed to the persistence
of the K76T mutation in Ethiopia. The use of CQ for
the treatment of vivax malaria in areas with CQR P. fal-
ciparum could increase the transmission of falciparum
malaria and the selection of mutant strains. In areas
where P. falciparum and P.vivax co-exist, mixed-species
infections are common and undoubtedly, CQ selective
pressure on P. falciparum is retained in such areas. None-
theless, some of these co-infections are often diagnosed as
vivax malaria by conventional microscopic examination
and treated with CQ, when cryptic CQR P. falciparum
infections emerge after treatment [34]. For instance, using
PCR, P. falciparum was identified in 18.7% (3/16) and
35.3% (6/14) of RDT-and microscopy-confirmed P. vivax
infections, respectively in the study area (unpublished).
The persistent use of CQ for the treatment of P. vivax
is, therefore, responsible for the absence of decline of
P. falciparum CQR in Ethiopia.
This is the first report in Ethiopia, to the best of author’s
knowledge, to uncover the presence of a single CQR
mutant pfcrt genotype, CVIET, the most prevalent haplo-
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type was not identified. Studies have shown that the
withdrawal of CQ in Kenya [15], Malawi [13], China
[35] and Tanzania [36], have resulted in the reversion
to the ancestral state of CQS from the CVIET haplotype.
In contrast, no change in the prevalence of the mutant
pfcrt allele occurred in Gabon [37,38] which changed its
national treatment guidelines from CQ to the combination
of artesunate plus aminoquinoline. But in Ghana [39]
which also changed its national treatment guidelines from
CQ to ACT (the combination of artesunate plus amino-
quinoline), a decrease in the prevalence of the mutant
pfcrt allele was observed in northern parts of the country.
Indeed, it is hardly possible to arrive at a definitive conclu-
sion as to whether the absence of CQ in the field or the
use of ACT has accounted for the re-emergence of wild
types for pfcrt [13,40]. Kamugisha et al., [41] attributed
the observed differences in the decline of CQR in
Mwanza, Tanzania and Iganga, Uganda to country-specific
drug change policies. Since the emergence of a new
haplotype can be spontaneous, continuous monitoring
is necessary as the SVMNT haplotype initially absent
from Africa suddenly appeared in Tanzania in 2004 [42].
Studies have shown that CQS parasites (pfcrt76K)
exhibited extensive diversity at all loci while CQR
strains (pfcrt76T) showed reduced diversity around
the pfcrt gene but high diversity for loci on other
chromosomes [39-42]. In this study, the CQR isolates
showed reduced diversity with respect to all MS
markers (two introns and two flanking). The isolates
were 89.9, 100, 88.6 and 100% identical with respect to
msint 2 (0 kb), msint 3 (0 kb), mscrt -2 (-2.814 kb) and
mscrt -29 (-29.268 kb), respectively. Although some allelic
combinations were shared among parasites collected from
asymptomatic subjects and clinical samples, there are
certain allelic combinations specific to each repertoire
isolate types. Of the seven haplotypes identified in the
study area, haplotye E1 is the most prevalent allelic
type. But whether these allelic combinations could be
linked to either symptomatic or asymptomatic infections
needs further research. It can be inferred from this study
that parasites identified from asymptomatic subjects are
more diverse than those present in symptomatic infections
(clinical) sample sets. Despite low malaria transmission
setting in the study area, asymptomatic parasite carriage is
still associated with a higher multiplicity of infection. The
number of MS alleles varied among the pfcrt introns and
flanking loci successfully analyzed, with msint 2 displaying
the greatest number of alleles (n = 4). On the other hand,
msint 3 and mscrt -29, showed no polymorphisms. In this
study, the CVIET mutant genotype showed variation in
11.1% (msint 2) and 13.4% (mscrt -2), but the isolates were
100% identical with respect to msint 3 and mscrt -29
allelic sizes. In P. falciparum strains, very low or noheterozygosity would be expected for msint 2 and msint 3
[8]. Diversity observed in msint 2 in this study is supported
by a study in a Papua New Guinea [43] that has indicated
the continuing evolution of the region’s parasite popula-
tions. Given that msint 2 and msint 3 are similar in their
length and nucleotide content, it is unclear why the mutant
strains show variability in msint 2 but not in msint 3. The
possible explanation for the observed reduction in MS
allelic diversity in the closest proximity to the pfcrt allele
is the result of strong CQ selection pressure. Because
CQ was responsible for homogenizing genetic diversity
at polymorphic sites in close physical linkage with CQR-
associated alleles [8].
Genetic diversity of the malaria parasite at a given region
is correlated with the local transmission intensity. It
has been indicated that drug selection tends to diminish
genetic diversity, especially near the resistance-determinant
locus [8]. The low heterozygocity of intronic and flanking
MS alleles observed in this study may indicate that parasite
population in the study area is genetically homogeneous,
which could be the result of the CQ-selective sweep.
Although analysis of MS loci around the pfcrt gene provides
suggestive evidence for selection around this gene, the
absence of parasites bearing sensitive pfcrt (CVMNK
haplotype) alleles in this population limits the strength
of this conclusion. Hence, it was difficult to compare
patterns of MS variation in both sensitive and resistant
pfcrt alleles in this study. The other limitation of this
study was the fact that other mutations at pfcrt codons
associated with CQR were not examined also absence of
mscrt -29 variations limits the conclusive power.
Conclusions
The present findings revealed the presence of only one
pfcrt mutant genotype, CVIET, in this study area. The
continued use of CQ for the treatment of P. vivax could
be one major reason for the persistence of mutant the
pfcrt allele in the study area. Given the incomplete with-
drawal of CQ in Ethiopia, no reversal to the wild-type
was observed although recent reports have shown that
removal of CQ pressure in Africa is associated with a
return of the wild-type pfcrt allele carrying strains and
CQ sensitivity. Since He was low both at intronic and
flanking MS loci, the isolates were more or less homo-
genous. Indeed, homogeneity is expected in resistant
parasites in areas where CQ has been widely used. The
genetic structure determined by introns- and pfcrt-flank-
ing markers indicates at least seven subpopulations of
Ethiopian P. falciparum isolates, circulating in the study
area. Further studies on the prevalence markers and
genetic diversity within parasite populations are required
in Ethiopia since the conclusions of the present study are
limited to samples collected in the study area.
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